clonidine has been researched along with Spinal Cord Diseases in 9 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Spinal Cord Diseases: Pathologic conditions which feature SPINAL CORD damage or dysfunction, including disorders involving the meninges and perimeningeal spaces surrounding the spinal cord. Traumatic injuries, vascular diseases, infections, and inflammatory/autoimmune processes may affect the spinal cord.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Despite leptomeningeal infection during prolonged treatment, epidural analgesia at the lumbar level provided analgesia using very large doses of local anesthetics combined with clonidine and morphine." | 3.72 | Epidural analgesia at end of life: facing empirical contraindications. ( Eikermann, M; Exner, HJ; Peters, J, 2003) |
| " Wide interpatient variability in the effective plasma concentrations of tizanidine means that the optimal dosage must be titrated over 2 to 4 weeks for each patient (dosages of 2 to 36 mg/day have been used in clinical trials)." | 2.40 | Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. ( Bryson, HM; Wagstaff, AJ, 1997) |
| "With the introduction of the antispasticity agent, tizanidine hydrochloride (Zanaflex), physicians have requested information about the optimal way to switch appropriate patients from baclofen to tizanidine." | 2.40 | An approach to switching patients from baclofen to tizanidine. ( Brenner, R; Hyman, N; Knobler, R; O'Brien, M; Stephan, T, 1998) |
| " It has low oral bioavailability and short halflife." | 1.56 | Optimization of Microemulgel for Tizanidine Hydrochloride. ( Brahmane, S; Chabukswar, A; Jagdale, S, 2020) |
| " Treatment was started with DS 103-282 at a mean dosage of 7." | 1.26 | The spasmolytic properties of 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1,3-benzothiadiazole hydrochloride (DS 103-282): a pilot study. ( Lakke, JP; Sie, OG, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Jagdale, S | 1 |
| Brahmane, S | 1 |
| Chabukswar, A | 1 |
| Nguyen, H | 2 |
| Le, C | 1 |
| Duarte, RV | 1 |
| Raphael, JH | 1 |
| Southall, JL | 1 |
| Baker, C | 1 |
| Ashford, RL | 1 |
| Exner, HJ | 1 |
| Peters, J | 1 |
| Eikermann, M | 1 |
| Ray, BK | 1 |
| Guha, G | 1 |
| Misra, AK | 1 |
| Das, SK | 1 |
| Sie, OG | 1 |
| Lakke, JP | 1 |
| Bastings, E | 1 |
| Rapisarda, G | 1 |
| Pepin, JL | 1 |
| Delwaide, PJ | 1 |
| Wagstaff, AJ | 1 |
| Bryson, HM | 1 |
| Brenner, R | 1 |
| Hyman, N | 1 |
| Knobler, R | 1 |
| O'Brien, M | 1 |
| Stephan, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Clinical Effect and Sonographic Findings of Kinesiotaping Combined With Therapeutic Exercise in Upper Extremity Spasticity and Function in Subacute Stroke Patients[NCT03024190] | 36 participants (Actual) | Interventional | 2017-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for clonidine and Spinal Cord Diseases
| Article | Year |
|---|---|
Intrathecal granuloma formation as result of opioid delivery: systematic literature review of case reports and analysis against a control group.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Analgesics, Opioid; Bupivacaine; Catheters; Catheters, Indwe | 2012 |
[Current pharmacological approach to the treatment of locomotion disorders due to spinal lesions].
Topics: Clonidine; Cyproheptadine; Humans; Locomotion; Spinal Cord Diseases; Spinal Cord Injuries | 1995 |
Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.
Topics: Adrenergic alpha-Agonists; Animals; Brain Diseases; Clinical Trials as Topic; Clonidine; Humans; Mus | 1997 |
An approach to switching patients from baclofen to tizanidine.
Topics: Baclofen; Clinical Competence; Clonidine; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Mus | 1998 |
5 other studies available for clonidine and Spinal Cord Diseases
| Article | Year |
|---|---|
Optimization of Microemulgel for Tizanidine Hydrochloride.
Topics: Administration, Cutaneous; Animals; Biological Availability; Cells, Cultured; Chickens; Clonidine; D | 2020 |
Cervical myelopathy from spinal sarcoidosis as the unexpected initial presentation for systemic sarcoidosis.
Topics: Adult; Cervical Vertebrae; Clonidine; Contrast Media; Gadolinium DTPA; Glucocorticoids; Humans; Hype | 2010 |
Epidural analgesia at end of life: facing empirical contraindications.
Topics: Abdominal Pain; Adrenergic alpha-Agonists; Adult; Analgesia, Epidural; Analgesics, Opioid; Anestheti | 2003 |
Involuntary jerking of lower half of the body (spinal myoclonus).
Topics: Baclofen; Clonazepam; Clonidine; Diagnosis, Differential; Humans; Lower Extremity; Middle Aged; Myoc | 2005 |
The spasmolytic properties of 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1,3-benzothiadiazole hydrochloride (DS 103-282): a pilot study.
Topics: Adult; Aged; Blood Pressure; Clonidine; Female; Humans; Male; Middle Aged; Parasympatholytics; Pilot | 1980 |